V. Leonardi

609 total citations
33 papers, 269 citations indexed

About

V. Leonardi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, V. Leonardi has authored 33 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in V. Leonardi's work include Cancer Treatment and Pharmacology (13 papers), Colorectal Cancer Treatments and Studies (9 papers) and HER2/EGFR in Cancer Research (7 papers). V. Leonardi is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Colorectal Cancer Treatments and Studies (9 papers) and HER2/EGFR in Cancer Research (7 papers). V. Leonardi collaborates with scholars based in Italy, United States and United Kingdom. V. Leonardi's co-authors include Vittorio Gebbia, Biagio Agostara, Roberto Valenza, S. Palmeri, Rosario Barone, G. Zummo, Marianna Bellafiore, Nicolò Borsellino, Francesco Ferraù and Marco Danova and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of the New York Academy of Sciences.

In The Last Decade

V. Leonardi

29 papers receiving 257 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Leonardi Italy 10 188 85 53 34 33 33 269
Nebojša Manojlović Serbia 8 215 1.1× 49 0.6× 54 1.0× 58 1.7× 46 1.4× 25 277
Loïc Bergougnoux France 6 221 1.2× 68 0.8× 28 0.5× 38 1.1× 22 0.7× 6 261
Bharathi Vennapusa United States 6 237 1.3× 106 1.2× 69 1.3× 32 0.9× 31 0.9× 15 312
Johan M. van Rooijen Netherlands 8 145 0.8× 58 0.7× 49 0.9× 37 1.1× 38 1.2× 16 224
Keita Uchino Japan 12 215 1.1× 151 1.8× 39 0.7× 86 2.5× 59 1.8× 40 357
Dany Gholam France 7 119 0.6× 33 0.4× 76 1.4× 24 0.7× 46 1.4× 16 289
Ignazio Martellucci Italy 11 280 1.5× 110 1.3× 73 1.4× 64 1.9× 43 1.3× 16 356
Ignacio Tusquets Spain 9 131 0.7× 110 1.3× 59 1.1× 50 1.5× 43 1.3× 16 252
Ines Miselevich Israel 8 180 1.0× 81 1.0× 62 1.2× 81 2.4× 87 2.6× 13 372
Akira Okimura Japan 8 141 0.8× 82 1.0× 49 0.9× 112 3.3× 67 2.0× 28 290

Countries citing papers authored by V. Leonardi

Since Specialization
Citations

This map shows the geographic impact of V. Leonardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Leonardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Leonardi more than expected).

Fields of papers citing papers by V. Leonardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Leonardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Leonardi. The network helps show where V. Leonardi may publish in the future.

Co-authorship network of co-authors of V. Leonardi

This figure shows the co-authorship network connecting the top 25 collaborators of V. Leonardi. A scholar is included among the top collaborators of V. Leonardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Leonardi. V. Leonardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Leonardi, V., et al.. (2024). Social Cognition and Covid-19: a rapid scoping review. Rivista di psichiatria. 59(6). 279–289.
3.
4.
Torrisi, Rosalba, Raffaella Palumbo, Rita De Sanctis, et al.. (2021). Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). Breast Cancer Research and Treatment. 190(1). 103–109. 2 indexed citations
5.
Fabi, Alessandra, Diana Giannarelli, Luca Moscetti, et al.. (2017). Ado-Trastuzumab Emtansine (T-DM1) in HER2+ Advanced Breast Cancer Patients: does Pretreatment with Pertuzumab Matter?. Future Oncology. 13(30). 2791–2797. 20 indexed citations
6.
Mazzola, Rosario, et al.. (2011). Capecitabine in Combination with Oxaliplatin as First-Line Therapy for Advanced Gastric Cancer: A Case Report. Tumori Journal. 97(1). 115–118. 1 indexed citations
7.
Leonardi, V., et al.. (2010). Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study. Oncology Letters. 1(4). 749–753. 4 indexed citations
8.
Barone, Rosario, Marianna Bellafiore, V. Leonardi, & G. Zummo. (2009). Structural analysis of rat patellar tendon in response to resistance and endurance training. Scandinavian Journal of Medicine and Science in Sports. 19(6). 782–789. 25 indexed citations
9.
Leonardi, V., et al.. (2006). Treatment of Metastatic Breast Cancer With Vinorelbine and Docetaxel. American Journal of Clinical Oncology. 29(3). 276–280. 5 indexed citations
10.
Gebbia, Vittorio, Salvatore Del Prete, Nicolò Borsellino, et al.. (2006). Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicenter Experience. Clinical Colorectal Cancer. 5(6). 422–428. 24 indexed citations
11.
Palmeri, S., Stefano Spada, Gianfranco Filippelli, et al.. (2005). Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study. Oncology. 68(4-6). 438–445. 16 indexed citations
12.
Palmeri, S., V. Leonardi, Manuela Tamburo De Bella, et al.. (2002). Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in Advanced Breast Cancer. Oncology. 63(3). 205–212. 8 indexed citations
13.
Palmeri, S., V. Leonardi, Vittorio Gebbia, et al.. (2001). Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial. Lung Cancer. 34(1). 115–123. 15 indexed citations
14.
Valenza, Roberto, V. Leonardi, Vittorio Gebbia, & Biagio Agostara. (2000). Gemcitabine and vinorelbine in pretreated advanced breast cancer: A pilot study. Annals of Oncology. 11(4). 495–496. 36 indexed citations
15.
Lorusso, Vito, Giovanni Di Vagno, Luigi Manzione, et al.. (1998). Combined Carboplatin plus Ifosfamide and Cisplatin in Patients with Advanced Ovarian Carcinoma. A Phase I–II Study. Gynecologic Oncology. 68(2). 172–177. 5 indexed citations
16.
Palmeri, S., Maria Meli, Marco Danova, et al.. (1998). 5-Fluorouracil plus interferon α-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: A multicentric randomized study. Journal of Cancer Research and Clinical Oncology. 124(3-4). 191–198. 9 indexed citations
17.
Palmeri, S. & V. Leonardi. (1997). Colorectal Cancer: Biological Aspects Prognosis Related and Follow-up. Tumori Journal. 83(1_suppl1). 21–22. 2 indexed citations
18.
Gridelli, Cesare, S. Palmeri, Modesto DʼAprile, et al.. (1996). Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. Annals of Oncology. 7(8). 821–826. 32 indexed citations
19.
Leonardi, V., et al.. (1996). Significance of microalbuminuria in atherosclerotic vascular disease. Archives of Gerontology and Geriatrics. 22. 173–177. 2 indexed citations
20.
Leonardi, V., Maria Meli, S. Palmeri, et al.. (1995). A Phase II Trial of Mitoxantrone plus Cyclophosphamide and 5-Fluorouracil in Modulation with Levo-Folinate for Advanced Breast Cancer Patients. Journal of Chemotherapy. 7(2). 160–166. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nebojša Manojlović Breakdown of academic impact, for papers by Loïc Bergougnoux Breakdown of academic impact, for papers by Bharathi Vennapusa Breakdown of academic impact, for papers by Johan M. van Rooijen Breakdown of academic impact, for papers by Keita Uchino Breakdown of academic impact, for papers by Dany Gholam Breakdown of academic impact, for papers by Ignazio Martellucci Breakdown of academic impact, for papers by Ignacio Tusquets Breakdown of academic impact, for papers by Ines Miselevich Breakdown of academic impact, for papers by Akira Okimura
Rankless by CCL
2026